In another murine SCC model, VEGF-D influenced the immune microenvironment by reducing Th2 inflammation, increasing CD8+ T cells, and decreasing CD4+ T cells, macrophages, and mast cells, leading to tumor regression in early stages. The gene discussed is VEGFD; the disease is neoplasm.